Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Richard T. Hoppe(Stanford Medicine), Ndiya Ogba(National Comprehensive Cancer Network), Joachim Yahalom(Unknown), Bouthaina S. Dabaja, Leo I. Gordon(Northwestern University), Kirsten M Boughan(Cleveland Clinic), Matthew McKinney, Monika L. Metzger(St. Jude Children's Research Hospital), Kami J. Maddocks(The Ohio State University), Vaishalee P. Kenkre(University of Wisconsin–Madison), Jennifer L. Burns(National Comprehensive Cancer Network), Alex F. Herrera(City of Hope), Rachel Rabinovitch(University of Colorado Boulder), Ephraim P. Hochberg(Massachusetts General Hospital), Randa Tao(University of Utah), Weiyun Z. Ai(City College of San Francisco), Philippe Armand(Harvard University), Jonathan McConathy(University of Colorado Cancer Center), Ranjana H. Advani(Stanford Medicine), David Morgan(Vanderbilt University Medical Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Richard F. Ambinder(Johns Hopkins University), Carolyn Mulroney(University of California San Diego Medical Center), Nadia Khan(Fox Chase Cancer Center), Patrick B. Johnston(Mayo Clinic in Arizona), Mark Kaminski(Sheba Medical Center), Karen C. Rosenspire(University of Pennsylvania), Cecil M. Benitez(Cancer Institute (WIA)), Jiayi Huang(Chongqing Medical University), Philip J. Bierman(Susan Thompson Buffett Foundation), Stuart Seropian(Yale Cancer Center), Jane N. Winter(Northwestern University), Celeste Bello(Moffitt Cancer Center), Ryan C. Lynch(Seattle Cancer Care Alliance)
Cited by 153
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k